[1]NCD RISK FACTOR COLLABORATION (NCDRISC). Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19·1 million participants[J]. Lancet, 2017, 389(10064):37-55.
[2]ARIMA H, BARZI F, CHALMERS J. Mortality patterns in hypertension[J]. J Hypertens, 2011, 29(Suppl 1): S3-S7.
[3]FITZMAURICE C, D ABATE, N ABBASI, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted LifeYears for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study [J]. JAMA Oncol, 2019, 5(12): 1749-1768.
[4]KIDOGUCHI S, SUGANO N, TOKUDOME G, et al. New concept of onco-hypertension and future perspectives[J]. Hypertension, 2021, 77(1):16-27.
[5]STOCKS T, VAN HEMELRIJCK M, MANJER J, et al. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project[J]. Hypertension, 2012, 59(4):802-810.
[6]CHRISTAKOUDI S, KAKOUROU A, MARKOZANNES G, et al. Blood pressure and risk of cancer in the European prospective investigation into cancer and nutrition[J]. Int J Cancer, 2020, 146(10):2680-2693.
[7]UMEMURA S, ARIMA H, ARIMA S, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019) [J]. Hypertens Res, 2019, 42(9):1235-1481.
[8]RENEHAN A G, TYSON M, EGGER M, et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies[J]. Lancet, 2008, 371(9612):569-578.
[9]CHOW W H, GRIDLEY G, FRAUMENI J F Jr, et al. Obesity, hypertension, and the risk of kidney cancer in men[J]. N Engl J Med, 2000, 343(18):1305-1311.
[10]WHO EXPERT CONSULTATION. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies[J]. Lancet, 2004, 363(9403):157-163.
[11]HESS K R. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions[J]. Stat Med, 1994, 13(10):1045-1062.
[12]FERRANNINI E, CUSHMAN W C. Diabetes and hypertension: The bad companions[J]. Lancet, 2012, 380(9841):601-610.
[13]SUVILA K, LANGN V, CHENG S S, et al. Age of hypertension onset: Overview of research and how to apply in practice[J]. Curr Hypertens Rep, 2020, 22(9):68.
[14]郭兰伟,李霓,王刚,等.BMI与恶性肿瘤发病风险的前瞻性队列研究 [J].中华流行病学杂志,2014,35(3): 231-236.
[15]MUOZ N, PLUMMER M, VIVAS J, et al. A case-control study of gastric cancer in Venezuela[J]. Int J Cancer, 2001, 93(3):417-423.
[16]SPAHILLARI A, MUKAMAL K J, DEFILIPPI C, et al. The association of lean and fat mass with all-cause mortality in older adults: The Cardiovascular Health Study[J]. Nutr Metab Cardiovasc Dis, 2016, 26(11):1039-1047.
[17]TAN B H, FEARON K C. Cachexia: prevalence and impact in medicine[J]. Curr Opin Clin Nutr Metab Care, 2008, 11(4):400-407.
[18]YANG Y, DONG J Y, SUN K K, et al. Obesity and incidence of lung cancer: A metaanalysis[J]. Int J Cancer, 2013, 132(5):1162-1169.
[19]BRENNAN P, MCKAY J, MOORE L, et al. Obesity and cancer: Mendelian randomization approach utilizing the FTO genotype[J]. Int J Epidemiol, 2009, 38(4):971-975.
[20]DOEHNER W,CLARK A,ANKER S D. The obesity paradox: Weighing the benefit[J]. Eur Heart J,2010, 31(2):146-148.
[21][ESLER M, LAMBERT G, SCHLAICH M, et al. Obesity paradox in hypertension: Is this because sympathetic activation in obesity-hypertension takes a benign form? [J]. Hypertension, 2018, 71(1):22-33. |